Johnson & Johnson will announce its third-quarter results on October 13. The company saw a 6.6% revenue increase in Q2 to $25.31 billion, driven by strong sales in its multiple myeloma portfolio and the drug Tremfya. Recent data suggests a significant survival benefit for patients using J&J's Tecvayli+Darzalex Faspro combination compared to standard care. Despite trading at a premium valuation, J&J's balanced risk/reward profile and promising drug pipeline make it a noteworthy investment to watch.
Following the anticipation of Johnson & Johnson's upcoming Q3 results, the stock is trading at USD 271.59 on Pluang as of Sep 29, 2026 20:02 WIB, showing a slight 0.13% decline in one day. The company holds a substantial market cap of $655.37 billion and a dividend yield of 1.97%, with most Pluang users currently selling, as indicated by an 86% sell order activity. Investors typically hold JNJ shares for about 129 days on the platform.
Johnson & Johnson announced new two-year data from a Phase 2/3 study showing that IMAAVY (nipocalimab) provides sustained disease control, improved muscle strength, and reduced corticosteroid use in adolescents with generalized myasthenia gravis (gMG...
Johnson & Johnson is poised for growth with a strong oncology and immunology pipeline, including promising drugs like CARVYKTI and TREMFYA showing significant progress. The company reported a 56% stock rally over the past year and raised earnings gui...
Procter & Gamble, Johnson & Johnson, and Coca-Cola have each increased their dividends annually through eight major economic downturns since the 1960s, including stagflation, recessions, and the pandemic. These companies have strong cash flows and so...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
Johnson & Johnson announced that its drug Tremfya significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 clinical trial. The STAR study showed Tremfya outperformed placebo in reducing disease activity a...
